Neuroendocrine Tumour (NET)

We provide local specialist NET care including:

• Specialist assessment and diagnosis

• Multidisciplinary team (MDT) decision-making

• Access to a full range of medical, surgical and interventional treatments

• Provide long-term follow-up and supportive care

• Dedicated Clinical Nurse Specialist CNS support

Care is delivered locally where possible, with referral to national centres for specific investigations or highly specialised treatments when required.

We provide personalised treatment for patients with neuroendocrine tumours, including:

• Surgery

• Endoscopic tumour ablation

• Percutaneous liver‑directed interventional treatments (e.g. radiofrequency ablation)

• Angiographic liver‑directed therapies (TAE, TACE, SIRT)

• Peptide Receptor Radionuclide Therapy (Lu‑177 PRRT). UHP offers PRRT locally, allowing eligible patients to receive advanced treatment in Plymouth.

• Medical therapies:

  • Somatostatin analogues

  • Chemotherapy

  • Targeted therapies

Patients have access to a range of investigations to support diagnosis and staging:

• Blood and urine hormone markers (e.g. chromogranin A, 5‑HIAA)

• CT and MRI imaging

• Histological diagnosis via biopsy

Patients with NETs often require long-term follow-up. This includes:

• Regular imaging (CT/MRI/nuclear medicine imaging)

• Biochemical monitoring

• Clinical review via MDT or specialist clinics

Follow-up is coordinated locally with input from specialist centres where required.

The NET CNS provides a key worker role for patients and families, including:

• Education and information about NETs

• Symptom management

• Coordination of care across services

• Psychological and supportive care

• Liaison with community and palliative care teams

The support group is open to all patients with a neuroendocrine tumour diagnosis and their families or carers. No referral is required and patients are welcome to attend any session. Should you wish to speak to us prior to attendance you can contact Maxine or Lesley.

Where: 

Arthur Read room, Memory Matter Café, 69a George Street, Plymouth, PL1 1RJ

Find the Memory Matter Cafe on google maps 

When:

• Friday 28 August 2026, 2pm to 4pm

• Friday 30 October 2026, 2pm to 4pm

Patients are discussed in a team to ensure collaborative decision-making. Our MDT works across the wider South West and includes input from colleagues at:

• Torbay Hospital

• Royal Devon University Healthcare (RDUH)

• Royal Cornwall Hospitals NHS Trust.

Members of the MDT include:

• Clinical Oncologist: Dr David Sherriff

• Nuclear Medicine Consultant: Dr Thomas Gruning

• Endocrinology Consultants: Dr Dan Flanagan, Dr Sherif Ghieth

• 6 HPB Consultant Surgeons: Miss Hitchins, Mr Briggs, Mr Stell, Mr Kanwar, Professor Aroori, Mr Bowles

• 2 Histopathologists: Dr Adam Douglas, Dr Jemimah Denson

• GI radiologists: Dr C Finan, Dr B Fox, Dr G Miles, Dr R Hodnett, Dr J Shirley, Dr A Abdellaoui, Mr A Mccormick.

• Clinical Nurse Specialist: Maxine Fagan

• Dietitians: Oncology dietetics team and HPB dietitians (surgical patients)

• MDT Coordinator: Will Hine

• Palliative care services

The MDT works closely with regional and national NET centres when required.

Referral Information

Referrals can be made via:

• EPIC

• Consultant-to-consultant referral

Please include:

• Clinical summary

• Imaging reports

• Histology (if available)

• Relevant blood results

Urgent cases should be discussed directly with the NET team.

Specialist imaging referral

Specialist imaging is accessed via referral pathways:

• Ga‑68 DOTATATE PET/CT: available via UCLH or Royal Free London

• FDG PET/CT: for selected cases

• Neuroendocrine Cancer UK

• UKI NETS - UK and Ireland Neuroendocrine Tumour Society

• ENETS - European Neuroendocrine Tumor Society

• Services at Mustard tree cancer support centre